Drug intelligence / Profile preview

KTX-0200

Development stage: Preclinical
Lead developer: Kintai Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**KTX-0200** is an oral small molecule anti-obesity agent developed by Kintai Therapeutics. It demonstrated sustained **14% body weight reduction** in 12-week chronic diet-induced obesity mouse and rodent models, alongside improvements in glucose control and liver health markers. The agent regulates carbohydrate absorption and increases colonic exposure to key microbial metabolites that act on human cells, advancing into IND-enabling studies for obesity treatment.[1][2][3][7][9][13]

Beyond the preview

Go deeper on KTX-0200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KTX-0200.

Explore the full profile